The dream product is a series of novel narrow-spectrum antibacterial agents that are able to cure any bacterial infection without induction of drug resistance, empowered by a one hour diagnostic test.
Antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections. CDC estimates that in the United States, more than two million people are sickened every year with antibiotic-resistant infections, with at least 23,000 dying as a result. There are high proportions of antibiotic resistance in bacteria that cause common infections (e.g. urinary tract infections, pneumonia, bloodstream infections) in all regions of the world. A high percentage of hospital-acquired infections are caused by highly resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant Gram-negative bacteria.
Watch the Video
Prof. Stephan Sieber’s (b. 1976) research field is bioorganic chemistry. The aim of his work is to develop new drugs for multidrug-resistant bacteria. His research is based on methods which combine synthetic chemistry, functional proteomics, cell biology and mass spectrometry. This approach enables the discovery of new active substances, some of which are currently being optimized for medical application.
2020 Award Ceremony
Video of the award ceremony that took place virtually on 13th July 2020View the entire virtual event